The Management of Prostatic Obstruction: How to Determine the Best Options?

Claus Roehrborn, T. McNicholas

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The two drug types commonly used to treat symptoms of benign prostatic hyperplasia (BPH), 5α-reductase inhibitors and α 1-blockers, have been shown to have different long-term effects on outcomes such as incidence of acute urinary retention (AUR) and BPH-related surgery. In addition, a comparative study of α1-blockers and 5α-reductase inhibitors in men with lower urinary tract symptoms showed that the treatment discontinuation rate is higher with α 1-blockers. The risk of treatment failure with α 1-blocker therapy has been shown to be related to baseline prostate volume, with greater failure rates with larger prostate sizes. Clinical data are now available on the dual 5α-reductase inhibitor, dutasteride. Three 2-year phase III randomised, double-blind, placebo-controlled studies have been performed in 4325 men with lower urinary tract symptoms, prostatic enlargement and likely bladder outlet obstruction due to BPH. Compared with placebo, dutasteride significantly improved symptoms from 6 months onwards (p < 0.001). Qmax improved significantly in dutasteride-treated patients from 1 month, and dutasteride treatment reduced the risk of AUR by 57% and the risk of BPH-related surgical intervention by 48% compared with placebo. Prostate volume was reduced by a mean of 25.9% and 28.5% at 1 and 2 years, respectively, in dutasteride-treated patients. The most common drug-related adverse events for dutasteride vs. placebo were erectile dysfunction (7% vs. 4%), decreased libido (4% vs. 2%), ejaculation disorders (2% vs. <1%) and gynaecomastia (2% vs. <1%). Adverse events occurred mostly in the first 6 months and their occurrence diminished with time.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalEuropean Urology, Supplement
Volume2
Issue number8
DOIs
StatePublished - Nov 2003

Fingerprint

Prostatic Hyperplasia
Placebos
Prostate
Lower Urinary Tract Symptoms
Oxidoreductases
Urinary Retention
Urinary Bladder Neck Obstruction
Libido
Ejaculation
Erectile Dysfunction
Drug-Related Side Effects and Adverse Reactions
Treatment Failure
Dutasteride
Therapeutics
Incidence
Pharmaceutical Preparations

Keywords

  • α-blockers
  • 5α-reductase inhibitors
  • Acute urinary retention
  • BPH
  • Dutasteride
  • MTOPS
  • Surgical intervention

ASJC Scopus subject areas

  • Urology

Cite this

The Management of Prostatic Obstruction : How to Determine the Best Options? / Roehrborn, Claus; McNicholas, T.

In: European Urology, Supplement, Vol. 2, No. 8, 11.2003, p. 13-19.

Research output: Contribution to journalArticle

@article{9dc39a4d482142168cc1f4608c294811,
title = "The Management of Prostatic Obstruction: How to Determine the Best Options?",
abstract = "The two drug types commonly used to treat symptoms of benign prostatic hyperplasia (BPH), 5α-reductase inhibitors and α 1-blockers, have been shown to have different long-term effects on outcomes such as incidence of acute urinary retention (AUR) and BPH-related surgery. In addition, a comparative study of α1-blockers and 5α-reductase inhibitors in men with lower urinary tract symptoms showed that the treatment discontinuation rate is higher with α 1-blockers. The risk of treatment failure with α 1-blocker therapy has been shown to be related to baseline prostate volume, with greater failure rates with larger prostate sizes. Clinical data are now available on the dual 5α-reductase inhibitor, dutasteride. Three 2-year phase III randomised, double-blind, placebo-controlled studies have been performed in 4325 men with lower urinary tract symptoms, prostatic enlargement and likely bladder outlet obstruction due to BPH. Compared with placebo, dutasteride significantly improved symptoms from 6 months onwards (p < 0.001). Qmax improved significantly in dutasteride-treated patients from 1 month, and dutasteride treatment reduced the risk of AUR by 57{\%} and the risk of BPH-related surgical intervention by 48{\%} compared with placebo. Prostate volume was reduced by a mean of 25.9{\%} and 28.5{\%} at 1 and 2 years, respectively, in dutasteride-treated patients. The most common drug-related adverse events for dutasteride vs. placebo were erectile dysfunction (7{\%} vs. 4{\%}), decreased libido (4{\%} vs. 2{\%}), ejaculation disorders (2{\%} vs. <1{\%}) and gynaecomastia (2{\%} vs. <1{\%}). Adverse events occurred mostly in the first 6 months and their occurrence diminished with time.",
keywords = "α-blockers, 5α-reductase inhibitors, Acute urinary retention, BPH, Dutasteride, MTOPS, Surgical intervention",
author = "Claus Roehrborn and T. McNicholas",
year = "2003",
month = "11",
doi = "10.1016/j.eursup.2003.09.010",
language = "English (US)",
volume = "2",
pages = "13--19",
journal = "European Urology, Supplements",
issn = "1569-9056",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - The Management of Prostatic Obstruction

T2 - How to Determine the Best Options?

AU - Roehrborn, Claus

AU - McNicholas, T.

PY - 2003/11

Y1 - 2003/11

N2 - The two drug types commonly used to treat symptoms of benign prostatic hyperplasia (BPH), 5α-reductase inhibitors and α 1-blockers, have been shown to have different long-term effects on outcomes such as incidence of acute urinary retention (AUR) and BPH-related surgery. In addition, a comparative study of α1-blockers and 5α-reductase inhibitors in men with lower urinary tract symptoms showed that the treatment discontinuation rate is higher with α 1-blockers. The risk of treatment failure with α 1-blocker therapy has been shown to be related to baseline prostate volume, with greater failure rates with larger prostate sizes. Clinical data are now available on the dual 5α-reductase inhibitor, dutasteride. Three 2-year phase III randomised, double-blind, placebo-controlled studies have been performed in 4325 men with lower urinary tract symptoms, prostatic enlargement and likely bladder outlet obstruction due to BPH. Compared with placebo, dutasteride significantly improved symptoms from 6 months onwards (p < 0.001). Qmax improved significantly in dutasteride-treated patients from 1 month, and dutasteride treatment reduced the risk of AUR by 57% and the risk of BPH-related surgical intervention by 48% compared with placebo. Prostate volume was reduced by a mean of 25.9% and 28.5% at 1 and 2 years, respectively, in dutasteride-treated patients. The most common drug-related adverse events for dutasteride vs. placebo were erectile dysfunction (7% vs. 4%), decreased libido (4% vs. 2%), ejaculation disorders (2% vs. <1%) and gynaecomastia (2% vs. <1%). Adverse events occurred mostly in the first 6 months and their occurrence diminished with time.

AB - The two drug types commonly used to treat symptoms of benign prostatic hyperplasia (BPH), 5α-reductase inhibitors and α 1-blockers, have been shown to have different long-term effects on outcomes such as incidence of acute urinary retention (AUR) and BPH-related surgery. In addition, a comparative study of α1-blockers and 5α-reductase inhibitors in men with lower urinary tract symptoms showed that the treatment discontinuation rate is higher with α 1-blockers. The risk of treatment failure with α 1-blocker therapy has been shown to be related to baseline prostate volume, with greater failure rates with larger prostate sizes. Clinical data are now available on the dual 5α-reductase inhibitor, dutasteride. Three 2-year phase III randomised, double-blind, placebo-controlled studies have been performed in 4325 men with lower urinary tract symptoms, prostatic enlargement and likely bladder outlet obstruction due to BPH. Compared with placebo, dutasteride significantly improved symptoms from 6 months onwards (p < 0.001). Qmax improved significantly in dutasteride-treated patients from 1 month, and dutasteride treatment reduced the risk of AUR by 57% and the risk of BPH-related surgical intervention by 48% compared with placebo. Prostate volume was reduced by a mean of 25.9% and 28.5% at 1 and 2 years, respectively, in dutasteride-treated patients. The most common drug-related adverse events for dutasteride vs. placebo were erectile dysfunction (7% vs. 4%), decreased libido (4% vs. 2%), ejaculation disorders (2% vs. <1%) and gynaecomastia (2% vs. <1%). Adverse events occurred mostly in the first 6 months and their occurrence diminished with time.

KW - α-blockers

KW - 5α-reductase inhibitors

KW - Acute urinary retention

KW - BPH

KW - Dutasteride

KW - MTOPS

KW - Surgical intervention

UR - http://www.scopus.com/inward/record.url?scp=0344014122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344014122&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2003.09.010

DO - 10.1016/j.eursup.2003.09.010

M3 - Article

AN - SCOPUS:0344014122

VL - 2

SP - 13

EP - 19

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 8

ER -